Efficacy and Tolerability of Nilvadipine in Combination with an Angiotensin II Receptor Antagonist in Patients with Essential Hypertension: A Multicenter, Open-Label, Uncontrolled Study

Open Label ◽

Uncontrolled Study

Assessment of effect of angiotensin II receptor antagonist losartan on aortic distensibility in patients with essential hypertension by echocardiography

Journal of Huazhong University of Science and Technology [Medical Sciences] ◽

10.1007/bf02857684 ◽

2002 ◽

Vol 22 (2) ◽

pp. 164-167 ◽

Cited By ~ 2

Author(s):

Yang Haoyi ◽

Deng Youbin ◽

Li Chunlei ◽

Bi Xiaojun ◽

Pan Min ◽

...

Keyword(s):

Essential Hypertension ◽

Angiotensin Ii ◽

Receptor Antagonist ◽

Aortic Distensibility ◽

Angiotensin Ii Receptor ◽

Effect of an angiotensin II receptor antagonist, candesartan, on insulin resistance and pressor mechanisms in essential hypertension

Journal of Human Hypertension ◽

10.1038/sj.jhh.1000748 ◽

1999 ◽

Vol 13 (S1) ◽

pp. S71-S74 ◽

Cited By ~ 35

Author(s):

K Higashiura ◽

N Ura ◽

Y Miyazaki ◽

K Shimamoto

Keyword(s):

Insulin Resistance ◽

Essential Hypertension ◽

Angiotensin Ii ◽

Receptor Antagonist ◽

Angiotensin Ii Receptor ◽

Hypotensive Effect of Losartan, a Nonpeptide Angiotensin II Receptor Antagonist, in Essential Hypertension

American Journal of Hypertension ◽

10.1093/ajh/6.1.28 ◽

1993 ◽

Vol 6 (1) ◽

pp. 28-32 ◽

Cited By ~ 75

Author(s):

Kazuo Tsunoda ◽

Keishi Abe ◽

Takeshi Hagino ◽

Ken Omata ◽

Seiichi Misawa ◽

...

Keyword(s):

Essential Hypertension ◽

Angiotensin Ii ◽

Receptor Antagonist ◽

Hypotensive Effect ◽

Angiotensin Ii Receptor ◽

Angiotensin-II receptor antagonist combined with calcium channel blocker or diuretic for essential hypertension

Hypertension Research ◽

10.1038/hr.2009.133 ◽

2009 ◽

Vol 32 (11) ◽

pp. 962-968 ◽

Cited By ~ 41

Author(s):

Toshihiko Ishimitsu ◽

Atsushi Numabe ◽

Toshihide Masuda ◽

Tomoyuki Akabane ◽

Atsushi Okamura ◽

...

Keyword(s):

Essential Hypertension ◽

Angiotensin Ii ◽

Calcium Channel ◽

Receptor Antagonist ◽

Calcium Channel Blocker ◽

Channel Blocker ◽

Angiotensin Ii Receptor ◽

A Single-Center, Open-Label, Randomized, Parallel-Group Study Assessing the Differences Between an Angiotensin II Receptor Antagonist and an Angiotensin-Converting Enzyme Inhibitor in Hypertensive Patients with Congestive Heart Failure: The Research for Efficacy of Angiotensin II Receptor Antagonist in Hypertensive Patients with Congestive Heart Failure Study

Current Therapeutic Research ◽

10.1016/s0011-393x(03)00020-1 ◽

2003 ◽

Vol 64 (2) ◽

pp. 81-94

Author(s):

Nobuo Totsuka ◽

Nobuhisa Awata ◽

Katsuhito Takahashi ◽

Hisako Yamamura ◽

Junko Nakamura ◽

...

Keyword(s):

Heart Failure ◽

Congestive Heart Failure ◽

Angiotensin Ii ◽

Receptor Antagonist ◽

Enzyme Inhibitor ◽

Angiotensin Ii Receptor ◽

Open Label ◽

Hypertensive Patients ◽

Parallel Group

EFFECT ON CENTRAL DISTENSIBILITY (C1) AND SYSTOLIC TIME INDEX (STI), WITH ANTIHYPERTENSIVE TREATMENT USING ACEIVS ANGIOTENSIN II RECEPTOR ANTAGONIST (ANA) IN ESSENTIAL HYPERTENSION

Journal of Hypertension ◽

10.1097/00004872-200402001-00383 ◽

2004 ◽

Vol 22 (Suppl. 1) ◽

pp. S90

Author(s):

E. Lopez-Vidriero Tejedor ◽

F. J. Rodriguez ◽

E. Lopez-Vidriero Abello

Keyword(s):

Essential Hypertension ◽

Angiotensin Ii ◽

Receptor Antagonist ◽

Antihypertensive Treatment ◽

Angiotensin Ii Receptor ◽

Time Index ◽

Systolic Time

Effects of an angiotensin II receptor antagonist on urinary albumin excretion, left ventricular mass, and systolic and diastolic blood pressures in essential hypertension

Current Therapeutic Research ◽

10.1016/s0011-393x(99)80005-8 ◽

1999 ◽

Vol 60 (5) ◽

pp. 295-303 ◽

Cited By ~ 1

Author(s):

Ayhan Karakoç ◽

Turgay Arinsoy ◽

Orkun Gençosmanolu ◽

Sükrü Sindel

Keyword(s):

Essential Hypertension ◽

Angiotensin Ii ◽

Receptor Antagonist ◽

Left Ventricular Mass ◽

Urinary Albumin Excretion ◽

Left Ventricular ◽

Urinary Albumin ◽

Angiotensin Ii Receptor ◽

Blood Pressures

Clinical Pharmacology of Multiple-Dose Losartan, an Angiotensin II Receptor Antagonist, in Patients with Essential Hypertension

The Journal of Clinical Pharmacology ◽

10.1002/j.1552-4604.1996.tb05026.x ◽

1996 ◽

Vol 36 (5) ◽

pp. 403-408 ◽

Cited By ~ 15

Author(s):

Masato Sasaki ◽

Akio Fujimura ◽

Kazuhiro Harada ◽

Ken-ichiro Sunaga ◽

Akio Ebihara

Keyword(s):

Clinical Pharmacology ◽

Essential Hypertension ◽

Angiotensin Ii ◽

Receptor Antagonist ◽

Multiple Dose ◽

Angiotensin Ii Receptor ◽

D56 Long-term safety and antihypertensive efficacy of irbesartan, the angiotensin II receptor antagonist: Pooled results of six open-label studies

American Journal of Hypertension ◽

10.1016/s0895-7061(97)89085-1 ◽

1997 ◽

Vol 10 (4) ◽

pp. 119A ◽

Cited By ~ 2

Author(s):

T LITTLEJOHN

Keyword(s):

Angiotensin Ii ◽

Receptor Antagonist ◽

Antihypertensive Efficacy ◽

Angiotensin Ii Receptor ◽

Open Label

Chronic hemodynamic and antifibrotic effects of a specific angiotensin II receptor antagonist (losartan) in bile duct ligated (BDL) rats and in portal vein ligated (PVL) rats

Journal of Hepatology ◽

10.1016/s0168-8278(01)80311-1 ◽

2001 ◽

Vol 34 (0) ◽

pp. 88

Author(s):

V Croquet

Keyword(s):

Angiotensin Ii ◽

Bile Duct ◽

Portal Vein ◽

Receptor Antagonist ◽

Angiotensin Ii Receptor ◽